To investigate the efficacy of fingolimod at the approved @ mg dose in patients early in the MS disease course , post hoc subgroup analyses of TRANSFORMS ( n = @ ) and FREEDOMS ( n = @ ) data were conducted in patients who experienced their first MS symptom < @ years before randomization .